Lotte Biologics, a South Korean contract development and manufacturing organization, and Merck's process solutions arm have entered into a strategic partnership for biopharmaceutical manufacturing and process development. This partnership involves Lotte Biologics purchasing raw materials and solutions from Merck for its pharmaceutical product development and production. Through this collaboration, Lotte Biologics aims to establish a stable supply chain system for raw materials, particularly in preparation for the commercial operation of its first biomanufacturing plant in Korea in 2027. Additionally, Lotte Biologics plans to expand its presence in the global CDMO market and support its biotech partners in securing raw materials. Merck's investment in a new bioprocessing production center in Daejeon will play a crucial role in supplying raw materials and solutions to Lotte Biologics' operations. This partnership represents a win-win strategy, aiming to position South Korea as a global leader in biopharmaceuticals beyond the areas of Songdo and Daejeon. It also underscores Lotte Biologics' commitment to providing research and development support to local biotech firms within its biomanufacturing complex, with the goal of driving scientific progress and impacting life and health. This agreement builds on a prior partnership between Lotte Biologics and Merck Group in 2022, highlighting the continued collaboration between the two organizations.